Literature DB >> 11458479

Patients' responses to risk information about the benefits of treating hypertension.

D Misselbrook1, D Armstrong.   

Abstract

BACKGROUND: The medical profession is often presented with information on the value of treatment in terms of likely risk reduction. If this same information was presented to patients--so enabling them to give proper informed consent--would this affect their decision to be treated? AIM: To examine patients' choice about treatment in response to different forms of risk presentation. DESIGN OF STUDY: Postal questionnaire study.
SETTING: The questionnaire was sent to 102 hypertensive patients and 207 matched non-hypertensive patients aged between 35 and 65 years in a UK general practice.
METHODS: Patients were asked the likelihood, on a four-point scale, of their accepting treatment for a chronic condition (mild hypertension) on the basis of relative risk reduction, absolute risk reduction, number needed to treat, and personal probability of benefit.
RESULTS: An 89% response rate was obtained. Of these, 92% would accept treatment using a relative risk reduction model, 75% would accept treatment using an absolute risk reduction model, 68% would accept treatment using a number needed to treat model, and 44% would accept treatment with a personal probability of benefit model.
CONCLUSION: Many patients may prefer not to take treatment for mild hypertension if the risks were fully explained. However, given that the form of the explanation has a strong influence on the patient's decision, it is not clear how decision-making can be fully shared nor what should constitute informed consent to treatment in this situation.

Entities:  

Mesh:

Year:  2001        PMID: 11458479      PMCID: PMC1313976     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  17 in total

1.  Screening in practice: Reducing the psychological costs.

Authors:  T M Marteau
Journal:  BMJ       Date:  1990-07-07

2.  Who benefits from medical interventions?

Authors:  G D Smith; M Egger
Journal:  BMJ       Date:  1994-01-08

3.  On the elicitation of preferences for alternative therapies.

Authors:  B J McNeil; S G Pauker; H C Sox; A Tversky
Journal:  N Engl J Med       Date:  1982-05-27       Impact factor: 91.245

4.  The effect of hypotensive drugs on the quality of life.

Authors:  S J Jachuck; H Brierley; S Jachuck; P M Willcox
Journal:  J R Coll Gen Pract       Date:  1982-02

5.  Can health screening damage your health?

Authors:  H G Stoate
Journal:  J R Coll Gen Pract       Date:  1989-05

6.  Risk factors for ischaemic heart disease: the prospective phase of the British Regional Heart Study.

Authors:  A G Shaper; S J Pocock; M Walker; A N Phillips; T P Whitehead; P W Macfarlane
Journal:  J Epidemiol Community Health       Date:  1985-09       Impact factor: 3.710

7.  Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society.

Authors:  P Sever; G Beevers; C Bulpitt; A Lever; L Ramsay; J Reid; J Swales
Journal:  BMJ       Date:  1993-04-10

8.  The framing effect of relative and absolute risk.

Authors:  D J Malenka; J A Baron; S Johansen; J W Wahrenberger; J M Ross
Journal:  J Gen Intern Med       Date:  1993-10       Impact factor: 5.128

9.  Increased absenteeism from work after detection and labeling of hypertensive patients.

Authors:  R B Haynes; D L Sackett; D W Taylor; E S Gibson; A L Johnson
Journal:  N Engl J Med       Date:  1978-10-05       Impact factor: 91.245

Review 10.  Sexual dysfunction with antihypertensive drugs.

Authors:  L M Prisant; A A Carr; P B Bottini; D S Solursh; L P Solursh
Journal:  Arch Intern Med       Date:  1994-04-11
View more
  19 in total

1.  Screening for cardiovascular risk: public health imperative or matter for individual informed choice?

Authors:  Theresa M Marteau; Ann Louise Kinmonth
Journal:  BMJ       Date:  2002-07-13

2.  Evaluation of benefit-risk.

Authors:  Silvio Garattini
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Is opportunistic disease prevention in the consultation ethically justifiable?

Authors:  Linn Getz; Johann A Sigurdsson; Irene Hetlevik
Journal:  BMJ       Date:  2003-08-30

4.  Medical decision making and the importance of baseline risk.

Authors:  Steven D Stovitz; Ian Shrier
Journal:  Br J Gen Pract       Date:  2013-11       Impact factor: 5.386

5.  Communicating risk.

Authors:  Louisa Polak
Journal:  Br J Gen Pract       Date:  2014-06       Impact factor: 5.386

6.  Patients' decisions about whether or not to take antihypertensive drugs: qualitative study.

Authors:  John Benson; Nicky Britten
Journal:  BMJ       Date:  2002-10-19

Review 7.  Describing treatment effects to patients.

Authors:  Annette Moxey; Dianne O'Connell; Patricia McGettigan; David Henry
Journal:  J Gen Intern Med       Date:  2003-11       Impact factor: 5.128

8.  The effect of how outcomes are framed on decisions about whether to take antihypertensive medication: a randomized trial.

Authors:  Cheryl L L Carling; Doris Tove Kristoffersen; Andrew D Oxman; Signe Flottorp; Atle Fretheim; Holger J Schünemann; Elie A Akl; Jeph Herrin; Thomas D MacKenzie; Victor M Montori
Journal:  PLoS One       Date:  2010-03-01       Impact factor: 3.240

9.  The ethics of information: absolute risk reduction and patient understanding of screening.

Authors:  Peter H Schwartz; Eric M Meslin
Journal:  J Gen Intern Med       Date:  2008-04-18       Impact factor: 5.128

10.  Gail model risk assessment and risk perceptions.

Authors:  John M Quillin; Elizabeth Fries; Donna McClish; Ellen Shaw de Paredes; Joann Bodurtha
Journal:  J Behav Med       Date:  2004-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.